Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Budesonide Inhalation Aerosol in Healthy Chinese Subjects
NCT06924190Completed
- Sponsor
- Lunan Better Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of budesonide in asthma (2 arms), sponsored by Lunan Better Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration at 12 days, Area under the plasma concentration versus time curve from time 0 to the last measurable concentration at 12 days and 1 more. Started Dec 2024; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06924190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924190.